- Open Access
Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw
© The Author(s). 2016
Received: 7 December 2015
Accepted: 18 July 2016
Published: 17 August 2016
Mesenchymal stem cells (MSCs) have been isolated from a variety of tissues, including bone marrow, adipose, and mucosa. MSCs have the capacity for self-renewal and differentiation. Reports have been published on the systemic administration of MSCs leading to functional improvements by engraftment and differentiation, thus providing a new strategy to regenerate damaged tissues. Recently, it has become clear that MSCs possess immunomodulatory properties and can therefore be used to treat diseases. However, the therapeutic effect mechanisms of MSCs are yet to be determined. Here, we investigated these mechanisms using a medication-related osteonecrosis of the jaw (MRONJ)-like mouse model.
To generate MRONJ-like characteristics, mice received intravenous zoledronate and dexamethasone two times a week. At 1 week after intravenous injection, maxillary first molars were extracted, and at 1 week after tooth extraction, MSCs were isolated from the bone marrow of the mice femurs and tibias. To compare “diseased MSCs” from MRONJ-like mice (d-MSCs) with “control MSCs” from untreated mice (c-MSCs), the isolated MSCs were analyzed by differentiation and colony-forming unit-fibroblast (CFU-F) assays and systemic transplantation of either d-MSCs or c-MSCs into MRONJ-like mice. Furthermore, we observed the exchange of cell contents among d-MSCs and c-MSCs during coculture with all combinations of each MSC type.
d-MSCs were inferior to c-MSCs in differentiation and CFU-F assays. Moreover, the d-MSC-treated group did not show earlier healing in MRONJ-like mice. In cocultures with any combination, MSC pairs formed cell–cell contacts and exchanged cell contents. Interestingly, the exchange among c-MSCs and d-MSCs was more frequently observed than other pairs, and d-MSCs were distinguishable from c-MSCs.
The interaction of c-MSCs and d-MSCs, including exchange of cell contents, contributes to the treatment potential of d-MSCs. This cellular behavior might be one therapeutic mechanism used by MSCs for MRONJ.
Medication-related osteonecrosis of the jaw (MRONJ) is defined as exposed necrotic bone in the oral cavity that displays intractable symptoms which cannot be cured for more than 8 weeks, and has never received radiation treatment . This condition appears to be nearly synonymous with bisphosphonate-related osteonecrosis of the jaw (BRONJ) . Nitrogen-containing bisphosphonates (BPs) are widely used anti-bone resorptive medicines, but they are well known to be associated with osteonecrosis of the jaw (ONJ) . The incidence of MRONJ in cancer patients who have received high doses of intravenous BPs, such as zoledronic acid, to inhibit cancer invasion and migration is much higher than that in patients receiving oral BP treatment for osteoporosis. To date, even though several risk factors, including invasive dental procedure, infection, mechanical trauma to the jaw bone, and use of both immunosuppressive and chemotherapy drugs, have connections with the onset of MRONJ [4–6], the mechanisms remain largely unknown. Additionally, because the etiology of MRONJ is not clear the fundamental method of clinical treatment for this disease is not recognized, and therefore novel treatments are required for immediate worldwide application.
Current symptomatic treatment of MRONJ involves conservative clinical approaches, including antibiotics, oral rinses, pain control, and limited debridement with the aim of reducing the stage of necrosis. We reported previously the positive effects of mesenchymal stem cells (MSCs) for the treatment of MRONJ [7, 8]. MSCs can self-renew and have the potential to undergo multidirectional differentiation. MSCs can differentiate into various lineages to secrete multiple cytokines and growth factors and restore their surrounding microenvironment. Therefore, MSCs have great potential for clinical therapy and have many applications in various fields of regenerative medicine . Of significant interest, MSCs are now well documented to be immune-privileged  and secretory cells of immunomodulatory factors [11, 12]. MSCs clearly have an immune-regulatory capacity , displaying immunosuppressive effects on certain conditions. Therefore, MSCs have the potential to cure inflammatory diseases. To date, the clinical application of MSCs has focused mainly on their potential for regenerative therapy, predominantly for myocardium, bone marrow, skin, bone, and cartilage tissues. More recently, however, immunomodulatory therapy has been trialed and found to be successful for graft-versus-host disease (GVHD), Crohn’s disease, aplastic anemia, cirrhosis, and multiple sclerosis, following systemic administration of MSCs. Indeed, MSCs have a great potential for clinical prevention and treatment of various autoimmune and inflammatory diseases. However, the detailed mechanisms of MSC therapy for any disease remain unknown, despite the large amount of obtained clinical and experimental data.
Essentially, the therapeutic target in MSC therapy has not been identified. Previous papers have reported MSC abnormalities from ovarectomy (OVX), scleroderma, and systemic lupus erythematosus (SLE) mouse models [14–16]. MSC abnormalities include partial changes in stemness, differentiation potential, proliferation, and colony formation. In some cases, therefore, the application of MSCs may worsen a patient’s condition. Namely, “disease treatment” may in fact mean “diseased MSC treatment”, and therefore it seems comprehensive that “diseased MSCs” (d-MSCs) are made the targets of treatment.
The relationship between MSC-based therapy and MSC function is not well understood. In this study, we hypothesized that administered MSCs may influence the host-diseased MSCs as the therapeutic target to act more efficiently to treat the disease. To test this hypothesis, we analyzed the therapeutic effect of MSCs with various inflammatory properties using a MRONJ mouse model to identify the mechanism of MSC therapy. This study aimed to examine the effectiveness and mechanism of MSC therapy for MRONJ, as well as investigating the pathogenesis of this disease.
C57BL/6 N mice (male, 6 weeks old; Kyudo Lab, Tosu, Japan) (n = 49) and GFP-transgenic C57BL/6 N mice (CAG-EGFP) (male, 6 weeks old; Japan SLC, Shizuoka, Japan) (n = 8) were used in this study. All animal experiments were performed under an institutionally approved protocol for the use of animal research at Kyushu University (approval number: A25-124-0).
Generation of diseased mouse model
The intact maxilla, kidney, liver, lung, spleen, femur, and tibia were harvested en bloc. In parallel, peripheral blood was collected for cytokine analysis.
ELISA of inflammation factors in blood
Peripheral blood was collected from the retro-orbital plexus of mice and centrifuged to obtain the blood serum . Culture supernatants from MSCs were collected . MSCs were extracted using M-PER® mammalian protein extraction reagent. The samples were centrifuged and used in an enzyme-linked immunosorbent assay (ELISA) for detection of interleukin (IL)-2, IL-6 and IL-10 (R&D Systems, Minneapolis, MN, USA).
After each experimental period, each organ was removed from euthanized mice and immersed in 4 % paraformaldehyde (PFA; pH 7.4) for 2 days. The maxilla and femur were then decalcified in 10 % tetrasodium ethylenediaminetetraacetate (EDTA). All samples were dehydrated in increasing concentrations of ethanol, embedded in paraffin, and sectioned in the coronal plane. The sections were stained with hematoxylin and eosin (H & E).
Isolation and culture of MSCs
MSCs were isolated from the bone marrow of mice as described previously . Briefly, bone marrow cells were flushed out of the mice femur and tibia bone cavities. The cells were passed through a 40-μm cell strainer to obtain a single cell suspension. The single cells were seeded at 1 × 106 cells/dish in 100-mm culture dishes. At 1 day after seeding, the cells were washed with phosphate-buffered saline (PBS) and cultured in growth medium consisting of alpha-minimum essential medium (α-MEM; Invitrogen, Grand Island, NY, USA) containing 20 % fetal bovine serum (FBS; Equitech-Bio, Kerrville, TX, USA), 2 mM l-glutamine (Invitrogen), 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). After 1 week of culture, the colony-forming unit-fibroblasts (CFU-Fs) had formed colonies. The adherent mesenchymal cells in these colonies were detached by trypsin/EDTA (Invitrogen), reseeded as new cultures, and expanded for further studies.
Osteogenic differentiation assay
MSCs (passage 2, 5 × 105 cells/dish) were grown on 35-mm dishes to confluence in growth medium and then cultured in osteogenic culture medium (growth medium containing 1.8 mM KH2PO4 and 10 nM Dex; both Sigma-Aldrich). After 28 days of osteogenic induction, the cultures were stained with a 1 % Alizarin Red S solution (Sigma-Aldrich).
Adipogenic differentiation assay
MSCs (passage 2, 5 × 105 cells/dish) were grown on 35-mm dishes to confluence in growth medium and then cultured in adipogenic culture medium (growth medium containing 0.5 mM isobutylmethylxanthine, 60 μM indomethacin, 0.5 μM hydrocortisone, and 10 μg/ml insulin; all Sigma-Aldrich). After 14 days of adipogenic induction, the cultures were stained with Oil Red O. The Oil Red O-positive lipid droplets were observed using an inverted microscope (BZ-9000; Keyence, Osaka, Japan).
MSCs (passage 2, 5 × 105 cells/dish) were grown on 35-mm dishes to confluence in growth medium and then cultured in endothelial culture medium (growth medium containing 0.5 mM isobutylmethylxanthine (Sigma-Aldrich), 2 mM l-glutamine (Invitrogen), 55 μM 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen)). After 14 days of endothelial induction, the cultures were stained with toluidine blue (Merck, Darmstadt, Germany). The formation of capillary-like structures (CLS) was observed using an inverted microscope.
MSCs (1 × 104) were seeded onto a FluoroBlok Insert with an 8.0-μm pore size (Corning, Corning, NY, USA) in a 24-well plate (BD Biosciences, Franklin Lakes, NJ, USA). After 2 days of culture, MSCs on the bottom of the FluoroBlok Insert were fixed with 4 % PFA (Merck) for 5 minutes at room temperature, and then stained with TRITC-phalloidin (1:400) for 2 hours. The cells were washed with 1 % PBS and mounted with VECTASHIELD Mounting Medium containing 4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA).
Cell proliferation was analyzed by a Click-iT® Plus EdU Imaging Kit (Thermo Fisher Scientific, Waltham, MA, USA). Cultured cells were exposed to 5-ethynyl-2′-deoxyuridine (EdU) for 2 or 4 hours and then fixed in 4 % PFA for 15 minutes followed by the inmation of a 0.5 % Triton® X-100. Fixed cells were treated with the Click-iT® reaction cocktail and phalloidin (1:100) for 15 minutes and then mounted with DAPI-containing medium.
The CFU-F assay was performed as described previously . Passage 1 MSCs were seeded in culture dishes (Nalge Nunc, Rochester, NY, USA). After 16 days of culture, the cells were stained with a solution of 0.1 % toluidine blue and 2 % PFA. Total colony numbers were counted per dish. Three independent experiments were performed.
MSCs isolated from bone marrow were cultured and passaged three times. These cells were injected (1 × 106 cells) into the mice with or without Dex/Zol via the tail vein (n = 5 in each group) at 24 hours after tooth extraction. In the control group, the mice received PBS (n = 5).
For in-vitro assessment, MSCs (2 × 104/dish) were seeded into 35-mm dishes and incubated with or without the other type of MSCs for 12 hours at 37 °C with 5 % CO2. Some MSCs were incubated in medium containing 100 nM chloromethyltetramethylrodamine (Mito, Mitotracker Orange CMTMRos; Molecular Probes, Eugene, OR, USA) for 20 minutes at 37 °C in the dark. After three washes with medium, the cells were examined under an inverted fluorescence microscope.
For in-vivo assessment, tissues were prepared according to the methods described in our previous reports [20, 21]. At the end of each experimental period, mice were deeply anesthetized and perfused intracardially with heparinized PBS, followed by 4 % PFA (pH 7.4). The maxillae were demineralized in 5 % EDTA for 4 days at 4 °C. The prepared site was cut into 10-μm bucco-palatal sections with a cryostat at −20 °C.
Immune-fluorescent staining of both in-vitro and in-vivo samples was carried out as follows. Samples were blocked with normal serum matched to secondary antibodies for 1 hour followed by incubation with mouse anti-rat green fluorescent protein (GFP) and CD90 antibodies (1:100; Sigma-Aldrich) overnight at 4 °C. Slides were then treated with FITC-conjugated secondary antibody (1:200; Jackson Immuno Research, West Grove, PA, USA) for 1 hour at room temperature (RT) and mounted with DAPI.
Data are expressed as means ± SD. One-way analysis of variance with Fisher’s least-significant difference test was performed. P < 0.05 was considered significant. Experiments were performed using triplicate samples and were repeated three or more times to verify their reproducibility.
MRONJ-like mouse model
Figure 1a details the experimental schedules and methods of our study. d-MSCs were isolated from the bone marrow obtained from the femurs and tibias of wild-type C57BL/6 N mice, which received both Dex and Zol administered intravenously for 2 weeks. For the control-MSCs (c-MSCs), the mice did not receive drug treatment before MSC isolation.
Characteristics of d-MSCs
d-MSCs from MRONJ mice had a higher proliferation rate compared with c-MSCs from normal mice, as estimated by EdU exposure and CFU-Fs (Fig. 1b). In d-MSCs, mineralized nodule formation stained by Alizarin Red S and the number of Oil Red O-positive cells and blood vessel-like structures per site/migrating cells were decreased following treatment with Zol and Dex. These data show that MRONJ disease is caused at the cellular rather than tissue level, for example by MSCs.
Symptoms of the disease model and therapeutic efficacy of MSCs
Next, we investigated the effects of MSC treatment on the levels of serum inflammatory cytokines, IL-2, IL-6, and IL-10 in MRONJ mice. In this particular case, MRONJ mice had higher IL-2 and IL-6 levels, and lower IL-10 levels than the controls. Moreover, these inflammatory cytokine levels in the c-MSC(+) model were similar to those in the controls. We identified abnormalities in several organs, including the lung, kidney, liver, and spleen, in the MRONJ model. All organs had obvious destruction of the typical structure, invasion of inflammatory cells, and necrosis of components. Interestingly, these inflammatory organ characteristics were recovered by c-MSCs but not d-MSCs.
Development of MRONJ in these treated mice was confirmed by a histological study that revealed a lack of epithelial lining in the alveolar socket. Moreover, necrotic bone was found adjacent to the area of intense inflammatory infiltrates, suggesting an association between inflammation and tissue necrosis in MRONJ-like disease. In contrast, 100 % of the MSC-treated mice showed complete epithelial coverage, which was confirmed by the histological study. In addition, abnormal MSCs from disease model mice were converted to normal MSCs after c-MSC treatment of MRONJ as shown in Fig. 4. These data indicated that MRONJ was caused by abnormal MSCs and could be recovered by treatment with normal MSCs. These data indicated that a cumulative dosage of Zol and Dex may be associated with the occurrence of MRONJ in mice undergoing dental extraction.
Accumulation of MSCs in the whole body
We showed the ability of i.v. transplanted MSCs to accumulate in various organs, including the dental extraction site. Many CD-90/GFP-FITC double-positive cells had accumulated in the lung, liver, spleen, and extraction site 1 day after MSC injection.
Intercellular exchange of MSCs
Some previous studies detail the transfection of mitochondria with microRNAs from MSCs to injured MSCs. Based on this consideration, we hypothesized that mitochondria were important for the therapeutic abilities of MSCs to regulate or cure injured cells. The next experiment investigated whether mitochondria have any relationship with MSC therapy. Figure 5 shows in-vitro analysis of d-MSCs and c-MSCs with red-stained mitochondria in direct coculture with GFP-expressing c-MSCs or d-MSCs, respectively. Interestingly, the red-stained mitochondria from c-MSCs were observed to actively move to d-MSCs. This result was consistent with the in-vivo study. As shown in Fig. 6b, many CD90(+) and GFP(−) cells with stained mitochondria were located in the upper portion of the socket. These results indicated mitochondrial exchange between exogenous and endogenous MSCs in MRONJ model mice. These data therefore indicate that MSCs may be able to cure d-MSCs via mitochondrial exchange.
In this study, establishment of the MRONJ mouse model was carried out based on our previous report . Because MRONJ is associated with high doses of BPs, Zol was administered at a dose at least 10 times greater than that used for humans to efficiently induce MRONJ (Fig. 1). Furthermore, the incidence of MRONJ-like disease in mice is enhanced by the combination of BP and Dex compared with Zol alone [7, 22]. Our method therefore ensured development of MRONJ to investigate clinical treatments.
To verify the development of MRONJ in our mouse model, maxillary bones were evaluated for clinical symptoms of MRONJ (Fig. 2), based on guidelines established by the American Association of Oral and Maxillofacial Surgeons and the American Society for Bone and Mineral Research . MRONJ model mice with open sockets and exposed bone were further assessed for MRONJ development using histological and biochemical methods to detect increased inflammation (Fig. 2). These procedures were carried out in a similar manner to a previous study in which inflammatory cells and necrotic bone areas with empty lacunae, fibrosis, and a lack of epithelial lining overlaid areas of dead bone .
Cell-based immunotherapy using systemic MSCs can potentially offer a safe and effective therapeutic modality in preventing the development of MRONJ disease. Furthermore, the mechanism of MSC treatment for MRONJ was shown to be the ability of transplanted MSCs to directly control and regulate d-MSCs in the patients. Moreover, mitochondria in the MSCs may play an important role in MSC regulation.
α-MSM, alpha-minimum essential medium; BP, nitrogen-containing bisphosphonate; BSA, bovine serum albumin; CFU-F, colony-forming unit-fibroblast; c-MSC, control mesenchymal stem cell; DAPI, 4′,6-diamidino-2-phenylindole; Dex, dexamethasone; d-MSC, diseased mesenchymal stem cell; EDTA, ethylenediaminetetraacetic acid; EdU, 5-Ethynyl-2′-deoxyuridine; FITC, fluorescein isothiocyanate; GFP, green fluorescent protein; GVHD, graft-versus-host disease; H & E, hematoxylin and eosin; i.v., intravenous; IL, interleukin; MRONJ, medication-related osteonecrosis of the jaw; MSC, mesenchymal stem cell; ONJ, osteonecrosis of the jaw; OVX, ovarectomy; PBS, phosphate-buffered saline; PFA, paraformaldehyde; SLE, systemic lupus erythematosus; TRITC, tetramethylrhodamine isothiocynate; Zol, zoledronate
This work was supported by a grant-in-aid for Scientific Research (C) No. 23592888 (to IA) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
YM, IA, YA, and RK were involved in the practical achievement of these experiments. YM, IA, AT, WO, and NU collected, analyzed, and interpreted the data. IA designed the study and provided financial and administrative support. IA, YA, YM, and KK wrote the manuscript. KK, TY, and YT revised the manuscript for publication. Each author participated sufficiently in the work to take public responsibility for appropriate portions of the content. All authors read and approved the manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72:1938–56.View ArticlePubMedGoogle Scholar
- Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA, American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2008;139:1674–7.View ArticlePubMedGoogle Scholar
- Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–7.View ArticlePubMedGoogle Scholar
- Early Breast Cancer Trialists’ Collaborative Group, Coleman R, Powles T, Paterson A, Gnant M, Anderson S, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–61.View ArticleGoogle Scholar
- Lopes RN, Rabelo GD, Rocha AC, Carvalho PA, Alves FA. Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution. J Oral Maxillofac Surg. 2015;73:1288–95.View ArticlePubMedGoogle Scholar
- Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg. 2011;40:277–84.View ArticlePubMedGoogle Scholar
- Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res. 2010;25:1668–79.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Q, Atsuta I, Liu S, Chen C, Shi S, Shi S, et al. IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin Cancer Res. 2013;19:3176–88.View ArticlePubMedGoogle Scholar
- Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2:83–92.PubMedGoogle Scholar
- Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890–6.View ArticlePubMedGoogle Scholar
- Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008;3:e1886.View ArticlePubMed CentralGoogle Scholar
- Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389–97.View ArticlePubMedGoogle Scholar
- Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.View ArticlePubMedGoogle Scholar
- Akiyama K, You YO, Yamaza T, Chen C, Tang L, Jin Y, et al. Characterization of bone marrow derived mesenchymal stem cells in suspension. Stem Cell Res Ther. 2012;3:40.View ArticlePubMedPubMed CentralGoogle Scholar
- Cipriani P, Marrelli A, Benedetto PD, Liakouli V, Carubbi F, Ruscitti P, et al. Scleroderma mesenchymal stem cells display a different phenotype from healthy controls; implications for regenerative medicine. Angiogenesis. 2013;16:595–607.View ArticlePubMedGoogle Scholar
- Yamaza T, Ren G, Akiyama K, Chen C, Shi Y, Shi S. Mouse mandible contains distinctive mesenchymal stem cells. J Dent Res. 2011;90:317–24.View ArticlePubMedPubMed CentralGoogle Scholar
- Atsuta I, Liu S, Miura Y, Akiyama K, Chen C, An Y, et al. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway. Stem Cell Res Ther. 2013;4:111.View ArticlePubMedPubMed CentralGoogle Scholar
- Kondo R, Atsuta I, Ayukawa Y, Yamaza T, Matsuura Y, Furuhashi A, et al. Therapeutic interaction of systemically-administered mesenchymal stem cells with peri-implant mucosa. PLoS One. 2014;9:e90681.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamaza T, Miura Y, Bi Y, Liu Y, Akiyama K, Sonoyama W, et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One. 2008;3:e2615.View ArticlePubMedPubMed CentralGoogle Scholar
- Atsuta I, Yamaza T, Yoshinari M, Goto T, Kido MA, Kagiya T, et al. Ultrastructural localization of laminin-5 (gamma2 chain) in the rat peri-implant oral mucosa around a titanium-dental implant by immuno-electron microscopy. Biomaterials. 2005;26:6280–7.View ArticlePubMedGoogle Scholar
- Atsuta I, Yamaza T, Yoshinari M, Mino S, Goto T, Kido MA, et al. Changes in the distribution of laminin-5 during peri-implant epithelium formation after immediate titanium implantation in rats. Biomaterials. 2005;26:1751–60.View ArticlePubMedGoogle Scholar
- Honda Y, Takahashi S, Zhang Y, Ono A, Murakami E, Shi N, et al. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. J Gastroenterol Hepatol. 2015;30:619–27.View ArticlePubMedGoogle Scholar
- Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67:61–70.View ArticlePubMedGoogle Scholar
- Veyrat-Masson R, Boiret-Dupre N, Rapatel C, Descamps S, Guillouard L, Guerin JJ, et al. Mesenchymal content of fresh bone marrow: a proposed quality control method for cell therapy. Br J Haematol. 2007;139:312–20.View ArticlePubMedGoogle Scholar
- Poltavtseva RA, Nikonova YA, Selezneva II, Yaroslavtseva AK, Stepanenko VN, Esipov RS, et al. Mesenchymal stem cells from human dental pulp: isolation, characteristics, and potencies of targeted differentiation. Bull Exp Biol Med. 2014;158:164–9.View ArticlePubMedGoogle Scholar
- Bernardo ME, Avanzini MA, Ciccocioppo R, Perotti C, Cometa AM, Moretta A, et al. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn’s disease. Cytotherapy. 2009;11:825–36.View ArticlePubMedGoogle Scholar
- Hou R, Liu R, Niu X, Chang W, Yan X, Wang C, et al. Biological characteristics and gene expression pattern of bone marrow mesenchymal stem cells in patients with psoriasis. Exp Dermatol. 2014;23:521–3.View ArticleGoogle Scholar
- Siegel G, Kluba T, Hermanutz-Klein U, Bieback K, Northoff H, Schafer R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013;11:146.View ArticlePubMedPubMed CentralGoogle Scholar
- Ramaswamy B, Shapiro CL. Bisphosphonates in the prevention and treatment of bone metastases. Oncology (Williston Park). 2003;17:1261–70. discussion 1270–2, 1277–8, 1280.Google Scholar
- Mognetti B, La Montagna G, Perrelli MG, Pagliaro P, Penna C. Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1alpha. J Cell Mol Med. 2013;17:287–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone. 2001;29:498–505.View ArticlePubMedGoogle Scholar
- Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98:10344–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Lonergan T, Brenner C, Bavister B. Differentiation-related changes in mitochondrial properties as indicators of stem cell competence. J Cell Physiol. 2006;208:149–53.View ArticlePubMedGoogle Scholar
- Mandal S, Lindgren AG, Srivastava AS, Clark AT, Banerjee U. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. Stem Cells. 2011;29:486–95.View ArticlePubMedPubMed CentralGoogle Scholar
- Prowse AB, Chong F, Elliott DA, Elefanty AG, Stanley EG, Gray PP, et al. Analysis of mitochondrial function and localisation during human embryonic stem cell differentiation in vitro. PLoS One. 2012;7:e52214.View ArticlePubMedPubMed CentralGoogle Scholar
- Varum S, Rodrigues AS, Moura MB, Momcilovic O, Easley CA, Ramalho-Santos J, Van Houten B, Schatten G. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One. 2011;6:e20914.View ArticlePubMedPubMed CentralGoogle Scholar
- Folmes CD, Nelson TJ, Terzic A. Energy metabolism in nuclear reprogramming. Biomark Med. 2011;5:715–29.View ArticlePubMedPubMed CentralGoogle Scholar
- Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells. 2010;28:721–33.View ArticlePubMedGoogle Scholar
- Spees JL, Olson SD, Whitney MJ, Prockop DJ. Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci U S A. 2006;103:1283–8.View ArticlePubMedPubMed CentralGoogle Scholar